SUBSCRIBE
SUBSCRIBE

Dana-Farber Cancer Institute

NEWS
Genetown
Dana-Farber Cancer Institute Scientists Create Custom Three-Dimensional Structures With “DNA Origami”
May 22, 2009
 · 
1 min read
Genetown
Can ‘Universal’ Flu Drug Stop Swine Flu?, Dana-Farber Cancer Institute And Harvard Medical School Study
May 15, 2009
 · 
1 min read
Bookmark and Share
Genetown
Vitamin D Aids Colon Cancer Treatment and Survival, Dana-Farber Cancer Institute Study
May 11, 2009
 · 
1 min read
Genetown
Some Radiation Therapy Treatments Can Decrease Fertility, Brigham and Women’s Hospital And Dana-Farber Cancer Institute Study
April 13, 2009
 · 
1 min read
Genetown
Heart Disease Marker Raises Cancer Risk, Too: Dana-Farber Cancer Institute And Harvard Medical School Study
March 23, 2009
 · 
1 min read
Blood Type, Pancreatic Cancer Risk Linked, Dana-Farber Cancer Institute Study
March 11, 2009
 · 
1 min read
Genetown
2 Markers Predict Survival Odds in Colon Cancer Patients, Dana-Farber Cancer Institute Study
December 12, 2008
 · 
1 min read
Drug Development
Possible AIDS Treatment Shows Promise in Monkeys, Yerkes National Primate Research Center, Dana-Farber Cancer Institute, Harvard Medical School And University of Pennsylvania Study
December 11, 2008
 · 
1 min read
Drug Development
Blocking Enzyme May Help Childhood Leukemia, Children’s Hospital Boston And Dana-Farber Cancer Institute Study
November 4, 2008
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
January 23, 2026
 · 
4 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
December 16, 2025
 · 
19 min read
Press Releases
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
December 16, 2025
 · 
19 min read
Press Releases
Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
December 8, 2025
 · 
7 min read
Press Releases
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
December 2, 2025
 · 
4 min read
Press Releases
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
November 20, 2025
 · 
4 min read
Press Releases
Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program
December 3, 2024
 · 
4 min read
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
October 15, 2024
 · 
4 min read
Pharm Country
Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer
January 30, 2024
 · 
2 min read
Genetown
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
November 9, 2023
 · 
5 min read
Load More